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E-mail: liu_fy@berkeley.eduExternal guide sequence (EGS) RNAs are associated with ribo-
nuclease P (RNase P), a tRNA processing enzyme, and repre-
sent promising agents for gene-targeting applications as they
can direct RNase-P-mediated cleavage of a target mRNA. Using
murine cytomegalovirus (MCMV) as a model system, we exam-
ined the antiviral effects of an EGS variant, which was engi-
neered using in vitro selection procedures. EGSs were used to
target the shared mRNA region of MCMV capsid scaffolding
protein (mCSP) and assemblin. In vitro, the EGS variant was
60 times more active in directing RNase P cleavage of the target
mRNA than the EGS originating from a natural tRNA. In
MCMV-infected cells, the variant reduced mCSP expression
by 92% and inhibited viral growth by 8,000-fold. In MCMV-in-
fected mice hydrodynamically transfected with EGS-expressing
constructs, the EGS variant was more effective in reducing
mCSP expression, decreasing viral production, and enhancing
animal survival than the EGS originating from a natural tRNA.
These results provide direct evidence that engineered EGS
variants with higher targeting activity in vitro are also more
effective in reducing gene expression in animals. Furthermore,
our findings imply the possibility of engineering potent EGS
variants for therapy of viral infections.
INTRODUCTION
Therapeutic RNA- or DNA-based agents, including those used in
RNAi and antisense therapy, have given great promise for future
treatment of illness.1,2 Every method using these agents contains its
own strengths and shortcomings regarding potency, possible effects
from nonspecific targeting of undesired genes, and challenges in
delivering the agents in vivo. Ribonuclease P (RNase P) is being devel-
oped as a promising gene-targeting agent to regulate expression of
mRNAs and proteins.3,4 During tRNAmaturation, RNase P enzymat-
ically removes the 50 leader sequence from a precursor to tRNA
(pre-tRNA).3,5,6 This enzyme catalyzes the hydrolysis of various natu-
rally occurring substrate molecules due to its unique capability to
recognize the structural formation of targeted substrates (Figure 1A).
In other words, RNase P can recognize and cleave any RNAmolecules322 Molecular Therapy: Nucleic Acids Vol. 9 December 2017 ª 2017 T
This is an open access article under the CC BY license (http://creatiresembling a tRNA-like complex in which a uniquely engineered
external guide sequence (EGS) binds to a target mRNA (Figure 1B)7,8.
EGSs were demonstrated in various experiments to guide and stimu-
late RNase P to cleave numerous target mRNAs of different hosts and
viruses and suppress the expression of these mRNAs in bacteria and
in cultured mammalian cells.8–14
Enhancing RNase-P-mediated cleavage efficiency by developing bet-
ter EGSs is critical to the usage of EGS-based technology for therapeu-
tic purposes in vivo. By applying a selection procedure in vitro, novel
EGS variants, which were capable of directing RNase-P-mediated
cleavage of the thymidine kinase (TK) mRNA of herpes simplex virus
1 (HSV-1) in vitro more efficiently than the EGS originating from a
naturally occurring tRNA, were identified.15 However, whether these
EGS variants can be used to suppress expression of viral genes and
treat infection in animal models has not been reported.
Human cytomegalovirus (CMV) is a medically important pathogen
that causes life-threatening complications in newborns and individ-
uals with a compromised immune system.16 In mice, infection and
pathogenesis of murine cytomegalovirus (MCMV) share many
similar aspects with human CMV in humans and could be used as
an animal model to further understand human CMV biology.17,18
For instance, CB17 SCID mice, which lack both T and B lymphocytes
and are favorably permissive to MCMV infection,16,19 can be used to
study the progression of CMV infection upon treatment of antivirals
in order to develop novel antiviral therapies.
In the study reported here, an EGS was engineered to bind to a shared
region of the mRNAs that encode MCMV assemblin and capsidhe Authors.
vecommons.org/licenses/by/4.0/).
Figure 1. RNase P Substrates
(A) A natural precursor to tRNA (ptRNA). (B) A target
mRNA (in red) hybridizing to an EGS (in purple). (C and D)
An mCSP mRNA sequence (in red) hybridizing to EGS
mCSP-SER (C) and mCSP-V832 (D) (in purple). The EGS
domain of mCSP-SER and mCSP-V832 originated from
tRNASer and variant V832, respectively.
www.moleculartherapy.orgscaffolding protein (mCSP), which are indispensable for capsid for-
mation and MCMV replication.16,20 Our experiments revealed that
the engineered EGS, mCSP-V832, was better at inhibiting MCMV
gene expression and reducing viral replication than mCSP-SER, the
EGS originating from a natural tRNA, resulting in a reduction in
mCSP expression of more than 92% and 8,000-fold reduced virus
production in cultured cells. In MCMV-infected severe combined
immunodeficiency (SCID) mice hydrodynamically transfected21–23
with constructs expressing engineered mCSP-V832, we observed sig-
nificant decreases in viral gene expression and replication and
increases in animal survival. To our knowledge, these experiments
show that engineered EGS variants have better efficacy in reducing
MCMV gene expression and infection in vivo than those derived
from a wild-type tRNA sequence. Furthermore, our findings imply
the possibility of engineering very potent EGS variants for the treat-
ment of viral infections.
RESULTS
RNase-P-Mediated Slicing of MCMV CSP mRNA Sequence
Directed by EGSs In Vitro
The mRNA coding for MCMV capsid scaffolding protein (mCSP) is
completely within and terminates at the identical 30 poly(A) location
with the mRNA coding for viral assemblin.24,25 Consequently, EGSs
can guide RNase P to cleave at the shared sequences of these two
mRNAs. In order to attain the highest efficiency of RNase-P-medi-
ated cutting, we attempted to identify the mCSP mRNA regions
that exhibit sequence features important for interactions with RNase
P and EGS to achieve efficient cleavage and that are potentially
exposed to hybridization of our constructed EGSs. These sequence
features include (1) the nucleotides 50 and 30 adjacent to the site ofMolecular Theracleavage as a pyrimidine and a guanosine,
respectively, and (2) an uracil 8 nt downstream
of the site of cleavage.3,26 A mapping method
with dimethyl sulfate (DMS)27–29 was employed
to reveal DMS-modified segments of the mCSP
mRNA. In these experiments, we grew MCMV-
infected cells in DMS-containing growth media.
The mCSP mRNA sequences subjected to DMS
modification were determined by primer exten-
sion experiments. We designated a site 195 nt
downstream of the CSP translational initiation
codon24,25,30 as the RNase P cutting site. This
location happens to be highly exposed to DMS
modification and thus probably open to EGS
hybridization. This site also has the sequencefeatures important for interactions with RNase P and EGS to achieve
efficient cleavage3,26 (Figure 1).
In earlier studies, we performed a selection process in vitro to identify
EGS RNA variants with higher efficiency to induce RNase P to cleave
a targeted mRNA than those EGSs originating from a tRNA.15 One
engineered variant, V832, exhibited one of the best activities in direct-
ing RNase P to cut the mCSP and HSV-1 TK mRNAs in vitro (see
below; Table 1).15 In the current study, we investigated the efficacy
of V832 in inhibiting MCMV infection in cultured cells and in mice.
Construction of functional EGS mCSP-V832, which shares similar
structure to a part of a tRNA consisting of a T-stem, a T-loop, and
a variable region, was performed by joining the EGS domain of
V832 to oligonucleotides that are complementary to the targeted
mCSPmRNA region (Figure 1D). We constructed another functional
EGS, mCSP-SER, from tRNASer similarly (Figure 1C). Control EGSs
mCSP-V832-C and mCSP-SER-C were similarly engineered from
mCSP-V832 and mCSP-SER, respectively. Compared to mCSP-
V832 and mCSP-SER, these two control EGSs had mutations
(50-UUC-30 / AAG) at the highly conserved region in the T-loop
(Figures 1C and 1D). These nucleotides31 have been shown to be
important for tRNA interaction with RNase P.3,6 EGSs with these
mutations failed to induce RNase-P-mediated cleavage.14,32
Functional EGSs mCSP-SER and mCSP-V832 were found to induce
RNase P to cleave substrate ms38 that contained the mCSP mRNA
sequence of 38 nt in vitro (Table 1). The RNase-P-mediated cleavage
efficiency [Vmax(apparent)/Km(apparent)] induced by mCSP-V832 was at
the minimum 60 times higher than that induced by mCSP-SER,py: Nucleic Acids Vol. 9 December 2017 323
Table 1. Kinetic Analyses of RNase P Cleavage Reactions for Substrates ptRNASer or mCSP mRNA Sequence (ms38) in the Presence of Different EGSs
Substrate Km (mM) Vmax (apparent) (pmol$min
1) Vmax(apparent)/Km(apparent) (pmol$mM
1$min1) KD (mM)
ptRNASer 0.020 ± 0.005 0.040 ± 0.015 2.0 ± 0.5
Substrate ms38
+mCSP-SER 0.60 ± 0.08 0.024 ± 0.010 0.040 ± 0.010 1.9 ± 0.4
+mCSP-SER-C ND ND <0.001 1.9 ± 0.5
+mCSP-V832 0.31 ± 0.08 0.78 ± 0.20 2.5 ± 0.5 0.022 ± 0.004
+mCSP-CV832-C ND ND <0.001 0.023 ± 0.004
Values were derived from experiments that were in triplicate and repeated three times. Experimental details are described in Materials and Methods. ND, not determined.
Molecular Therapy: Nucleic Acidswhich originated from a natural tRNA (Table 1). The targeting activ-
ity of mCSP-V832 increases, probably because of additional EGS-
mRNA tertiary interactions that may induce further stabilization of
the mCSP-V832-ms38 complex. For this hypothesis to be true, we
anticipate that mCSP-V832 may hybridize to ms38 better than
mCSP-SER. EGS mCSP-V832 has 80 times higher binding affinity
(as measured by the dissociation constant [KD]) to ms38 than mCSP-
SER (Table 1). Since mCSP-V832 and mCSP-SER share identical
sequences complementary to ms38 (Figures 1C and 1D), these results
raise the possibility that variant mCSP-V832 may have enhanced
tertiary interactions with substrate ms38, resulting in better hybridi-
zation and stability of the EGS-target complex and leading to more
efficient RNase-P-mediated cleavage.
With control EGSs mCSP-SER-C and mCSP-V832-C, RNase-P-asso-
ciated cleavage of ms38 was rarely observed and was at least 2,500
times slower than that observed for mCSP-V832 (Table 1). CSP-
SER-C and mCSP-V832-C shared identical sequences complemen-
tary to the mCSP mRNA sequence as mCSP-SER and mCSP-V832
(Figures 1C and 1D) and showed comparable binding affinities
(KD) in vitro to ms38 as mCSP-SER and mCSP-V832, respectively
(Table 1). Hence, we used mCSP-V832-C and mCSP-SER-C as
controls for the antisense effect of these EGSs.
Expression of the Engineered EGSs in Tissue Culture Settings
We selected retroviral LXSN vector and U6 RNA promoter to express
EGSs.32,33 Cell lines expressing mCSP-SER, mCSP-SER-C, mCSP-
V832, and mCSP-V832-C were derived from NIH 3T3 cells. We
also produced another cell line expressing TK112,34 an EGS that tar-
gets the HSV-1 TK mRNA. With TK112, we observed no RNase-
P-mediated cleavage of ms38 in vitro (data not shown). TK112 was
selected to examine whether EGS RNA with an improper guide
sequence would induce RNase P to cleave themCSPmRNA sequence.
Northern blot analyses were used to quantify EGS RNA expression in
each cloned cell line, and expression levels of mouse RNase P RNA
served as the loading control (Figure 2, lanes 1–8).3,35 Only cell lines
expressing the same levels of the EGS RNAs were used for subsequent
studies. In our 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) experiments, the control cells, which only contained
the LXSN vector alone, were similar to the EGS-expressing cells with
regard to their growth and viability for up to 90 days (data not324 Molecular Therapy: Nucleic Acids Vol. 9 December 2017shown). These studies suggest that EGS expression may not affect
cell growth and viability.
Inhibition of MCMV Gene Expression and Production by EGS in
Cultured Cells
To establish how effectively the EGSs can inhibit MCMV gene expres-
sion, total RNAs were obtained from cells infected with MCMV (MOI
of 1) at 8–72 hr postinfection. Viral 7.2-kb RNA expression36,37 was
used as the internal control to quantify the levels of mCSP and assem-
blin mRNAs (Figure 2, lanes 9–12). A decline of 92%–93% and
75%–76% in the expression levels of assemblin and mCSP mRNAs
was documented in cells expressing mCSP-V832 and mCSP-SER,
respectively (Figure 2, lanes 13–16; Table 2). On the other hand, a
decrease in the expression levels of the two mRNAs of less than
10% was documented in cells expressing mCSP-V832-C, mCSP-
SER-C, or M1-TK (Figure 2, lanes 13–16; Table 2). Using northern
blot analyses and rapid amplification cDNA ends (RACE) PCR assays,
we detected no specific products of cleavage of the viral mRNAs by
RNase P in these cells, possibly because these cleavage products, which
are RNAs lacking either a 50 cap structure or a 30 poly(A) sequence, are
extremely unstable and quickly hydrolyzed intracellularly.
We used western blot experiments to assay MCMV mCSP protein
expression (Figure 2, lanes 21–24) with mouse actin as the internal
control (Figure 2, lanes 17–20). Viral mCSP protein expression
decreased by 92%–93% and 74%–75% in cells expressing mCSP-
V832 and mCSP-SER RNA, respectively, and by 10% (or less) in cells
expressing mCSP-V832-C or mCSP-SER-C RNA (Table 2). These
observations suggest that the substantial decline in the levels of the
mCSP mRNA and protein expression in cells expressing mCSP-
V832 and mCSP-SER resulted from RNase-P-catalyzed cleavage of
the target mRNA directed by the EGSs. The low level of repression
in mCSP expression found in cells expressing mCSP-V832-C and
mCSP-SER-C likely resulted from an antisense effect. This is because
these control EGSs had similar binding affinities to the targeted
mRNA as mCSP-V832 and mCSP-SER, respectively, but could not
induce RNase-P-mediated cleavage, because there were point muta-
tions in their T-loop segments.
We studied the inhibition of MCMV production in the cells express-
ing EGSs by infecting cells with MCMV at an MOI of 1. 4 days
Figure 2. Expression of EGS RNAs, and MCMV mRNAs, and Proteins in Cultured Cells
(A) RNA samples (30 mg) from parental NIH 3T3 cells () and EGS-expressing cells were separated on 2%agarose gels containing formaldehyde (lanes 1–8). (B) RNA samples
(50 mg) were harvested from parental NIH 3T3 cells () and EGS-expressing cells infected with MCMV (MOI = 1) at 36 hr postinfection and then separated on 8% denaturing
polyacrylamide gels containing urea (lanes 9–16). (C) Protein samples (60 mg) were prepared from parental NIH 3T3 cells () and EGS-expressing cells infected with MCMV
(MOI = 1) at 48 hr postinfection and separated on 9% SDS polyacrylamide gels. Separated RNA and protein fractions were transferred to nitrocellulose membranes and then
reacted with a [32P]-radiolabeled probe for the DNA sequences coding for mouse RNase P RNA (lanes 1–4), EGSs (lanes 5–8), MCMV 7.2-kb RNA (lanes 9–12), and mCSP
mRNA (13–16) or antibodies against mouse actin (lanes 17–20) and MCMV mCSP (lanes 21–24).
www.moleculartherapy.orgpostinfection, viral production decreased by at least 8,000- and 700-
fold in cells that expressed mCSP-V832 and mCSP-SER, respectively
(Figure 3). No significant decrease was documented in cells express-
ing mCSP-V832-C, mCSP-SER-C, or TK112 (Figure 3). Thus, EGSs
that inhibit mCSP expression reduce MCMV production and growth.
Inhibition of MCMV Capsid Formation by EGS RNA-Directed
Targeting of mCSP mRNA
Reducing mCSP expression could result in inhibition of MCMV lytic
replication, because mCSP is crucial for viral capsid assembly.24,25
There is a possibility that the documented decline of viral production
in the EGS-expressing cells results not from RNase-P-mediated
slicing of the mCSP/assemblin mRNAs directed by the EGSs but
from other effects of the EGSs on viral lytic replication, such as inhi-
bition of viral immediate early genes or genomic DNA replication.16
To address these issues and study the specificity of EGS-directed
RNase P cleavage, two series of experiments were performed to
examine the steps of the viral lytic cycle in the EGS-expressing cells
and study the antiviral effects of the EGSs.
We assayed MCMV gene expression in EGS-expressing cells in the
first series of experiments. Blocking mCSP and assemblin expression
is not anticipated to alter the expression of other MCMV genes,
including a (immediate-early), b (early), and g (late) genes, which
are not controlled by mCSP or assemblin.16 We used northern blot
experiments to quantify the levels of viral M36 (an immediate-early
transcript) and M44 mRNAs (an early and late transcript). Further-
more, western blot analyses were employed to quantify the protein
levels of mie1 (an immediate-early protein), M112 (an early and
late protein), and M99 (a late protein). No noteworthy difference in
the expression levels of these MCMV genes was observed among
EGS-expressing cells and parental NIH 3T3 cells (Table 2).
Thus, mCSP-SER and mCSP-V832 expression seemed to hinder theexpression of CSP and assemblin explicitly but did not alter the
expression of other MCMV genes.
We examined the possibility that MCMV genomic replication and
capsid development were altered in the cells expressing mCSP-SER
and mCSP-V832 RNAs in the second series of experiments. A semi-
quantitative PCR assay for the detection of viral mie1 sequence was
carried out to determine intracellular level of MCMV DNA in the
total DNA samples isolated from infected cells. Levels of mouse actin
DNA were used as the internal control (Figure 3, lanes 1–4). The level
of intracellular MCMV DNA signifies the production level of the
MCMV genome, because the viral DNA genome presents as an
episome that is not integrated into mouse chromosomes.16 We also
examined the level of encapsidated viral DNA in order to study
mature MCMV capsid formation within the cells. We used DNase I
to treat DNA samples from the lysates of infected cells. The packaged
MCMV DNA sequences are not anticipated to be susceptible to
DNase I treatment while the DNA sequences that are not “encapsi-
dated” are subjected to DNase I digestion. PCR quantification of
the levels of the viral mie1 sequence in samples treated with DNase
I was performed to determine the encapsidated MCMV DNA levels
(Figure 3, lanes 5–8).
We found no significant difference in the levels of total intracellular
(both “packaged” and “un-packaged”) MCMV DNA in the EGS-ex-
pressing cells (Figure 3, lanes 1–4). When the samples were first
treated with DNase I and then subjected to PCR assays, the levels
of “packaged” viral DNA were notably lower in cells expressing
mCSP-SER and much lower in cells expressing mCSP-V832 than in
cells expressing no EGS or the control EGSs mCSP-SER-C, mCSP-
V832-C, or TK112 (Figure 3, lanes 5–8). These findings suggest
that inhibiting mCSP and assemblin expression by EGS-directed
RNase P cleavage has no effect on the replication of MCMV DNAMolecular Therapy: Nucleic Acids Vol. 9 December 2017 325
Table 2. Reduction in the Level of Viral Gene Expression in EGS-Expressing Cells and NIH 3T3 Cells
Viral Gene Class
EGS RNA
NIH 3T3 TK112 mCSP-SER-C mCSP-V832-C CSP-SER mCSP-V832
M36 mRNA a 0% 0% 1% 0% 0% 0%
m44 mRNA b 0% 0% 1% 1% 1% 1%
mCSP mRNA g 0% 0% 5% 6% 76% ± 8% 93% ± 7%
Assemblin mRNA g 0% 0% 5% 6% 75% ± 8% 92% ± 8%
mie1 protein a 0% 0% 1% 1% 0% 0%
M112 protein b,g 0% 0% 0% 0% 0% 0%
CSP protein g 0% 0% 5% 7% 74% ± 8% 92% ± 8%
Assemblin protein g 0% 0% 6% 6% 75% ± 8% 93% ± 9%
M99 protein g 0% 0% 0% 1% 1% 0%
The values are derived from experiments that were repeated three times. SDs less than 5% are not shown.
Molecular Therapy: Nucleic Acidsbut results in the blockage of the steps when the capsid is formed.
Moreover, the selected EGS variant (i.e., mCSP-V832) had better
efficacy in inhibiting HCMV capsid development than the EGS
(i.e., mCSP-SER) originating from a natural tRNA. Different from
most currently US Food and Drug Administration (FDA)-approved
compounds (e.g., ganciclovir), which block HCMV genomic DNA
replication,16 the EGSs mCSP-V832 and mCSP-SER exhibited a
unique mode of antiviral action by blocking HCMV capsid matura-
tion without affecting viral genomic DNA replication. The results
presented here further suggest that this unique mode of action can
effectively inhibit HCMV infection and progeny production.
Inhibition of MCMV Infection and Pathogenesis by EGSs in
Animals
MCMV infection of immunodeficient SCID mice represents an
outstanding model for studying CMV biology and investigating the
antiviral activity of various compounds and therapeutic
approaches.19,38 To study whether EGSs affect MCMV infection
in vivo, groups of SCID mice (5 animals per group) were infected
with MCMV (1  104 plaque-forming units [PFU]/animal) and
transfected hydrodynamically21–23 with plasmids carrying LXSN-
EGS DNA at 24 hr postinfection. We repeated the transfection every
3 days to provide continuous expression of EGSs. We determined
transfection efficiency by assaying the expression of EGS RNAs in
the tissues using northern blot analysis with the expression of mouse
RNase P RNA as the internal control (Figure 4, lanes 1–8). Further-
more, the transfection efficiency was also assessed by examining the
expression of GFP, whose coding sequence is also located in the
LXSN vector (data not shown). We found considerable amounts of
EGS and a substantial number of cells expressing GFP in the spleens
and livers of transfected mice, suggesting that the hydrodynamic
transfection procedure was efficient, as previously reported by other
investigators21–23 (Figure 4B; data not shown).
We performed three series of experiments to understand the effects
of EGSs on MCMV virulence and infection in vivo. In the first series
of experiments, we measured the survival rates of the mice trans-326 Molecular Therapy: Nucleic Acids Vol. 9 December 2017fected with the mCSP-V832 and mCSP-SER plasmids in comparison
with those injected with only PBS or PBS with plasmid constructs
containing the sequences of the control EGSs mCSP-V832-C,
mCSP-SER-C, or M1-TK. All uninfected mice hydrodynamically
transfected with EGS-LXSN survived and showed no adverse symp-
toms for at least 3 months. Similar results were also found in
untreated and uninfected mice (data not shown). The survivability
of MCMV-infected animals transfected with the mCSP-V832-C,
mCSP-SER-C, or M1-TK plasmids was similar to that of animals
receiving only PBS, as all of these infected animals died within
26–27 days postinfection (Figure 5). On the other hand, the surviv-
ability of infected animals that expressed mCSP-V832 and mCSP-
SER enhanced drastically, as no mice died until 80 and 50 days
postinfection, respectively (Figure 5).
In the second series of experiments, we examined MCMV growth in
various organs of mice during a 3-week infection phase prior to the
onset of death of the infected mice in order to understand the benefits
or consequences of EGS expression in SCID mice. At 1, 3, 7, 10, 14,
and 21 days postinfection, we collected the spleens, livers, and salivary
glands from euthanized animals and assessed viral infection and
production by determining virus titers in these tissues.19,38 The viral
titers in each of the organs from mice injected with control EGS (i.e.,
mCSP-V832-C, mCSP-SER-C, or M1-TK) constructs were identical
to those in the same organs from mice injected with only PBS, sug-
gesting that these control EGSs do not affect MCMV infection and
production in vivo (Figures 6A–6C). On the other hand, the titers
of MCMV in the organs from mice injected with the functional
EGS (i.e., mCSP-V832 and mCSP-SER) constructs were steadily
lower than those from mice injected with only PBS during the entire
21-day infection phase. At 3 weeks postinfection, the MCMV titers in
the spleens, livers, and salivary glands of the mCSP-V832-injected
mice were lower than those from mice injected with PBS only by
2,500-, 2,000-, and 20,000-fold, respectively (Figure 6). The MCMV
titers in the spleens, livers, and salivary glands of the mCSP-SER-in-
jected mice were lower than those of mice injected with PBS only by
200-, 250-, and 1,500-fold, respectively (Figure 6). These observations
Figure 3. Growth of MCMV and Level of Encapsidated (Lanes 5–8) and Total
Intracellular (Lanes 1–4) Viral DNA in Cultured Cells
Experiments were performed as described in Materials and Methods. Virus stocks
were titered using plaque assays.19 SD is indicated by error bars. These values are
derived from experiments that were in triplicate and repeated three times. DNA
samples (lanes 1–8) were prepared from MCMV-infected cells (MOI of 2) at 48 hr
postinfection. Levels of MCMV mie1 sequence were assayed by PCR using mouse
actin DNA sequence as internal controls. The [32P]-labeled PCR products were
separated in nondenaturing gels.
www.moleculartherapy.orgimply that mCSP-V832 and mCSP-SER expression reduces MCMV
infection and production in vivo.
In the third series of experiments, we studied MCMV gene expression
in the organs. At 2 weeks postinfection, we detected substantial levels
ofMCMVassemblin/mCSPmRNAs andmCSPprotein in the livers of
the animals expressing control EGSs mCSP-V832-C, mCSP-SER-C,
and TK112 (Figure 4, lanes 9–20). However, we detected no noticeable
expression of assemblin/mCSP mRNAs and mCSP protein in mCSP-
V832- and mCSP-SER-treated animals at the same time points (Fig-
ure 4, lanes 9–20; data not shown). Notably, we observed no difference
in the expression of mCSP mRNA and protein between mice injected
with PBS only and those transfected with plasmids containing control
EGSs mCSP-V832-C, mCSP-SER-C, or TK112 sequences (Figure 4,
lanes 9–20). These findings indicate that viral infection is repressed
in mice treated with mCSP-V832 and mCSP-SER constructs.DISCUSSION
The technology based on RNase-P-associated EGS signifies an
appealing method for therapeutic application.3,4 Nevertheless, the
knowledge regarding the rate-limiting step of EGS-based targeting
in tissue culture and in animals and how to improve the efficiency
of EGS-based technology is currently limited. In this report, an
EGS was engineered to target an accessible region of the MCMV
mCSP mRNA that contained sequence features important for inter-
action with EGS and RNase P to achieve efficient cleavage. We hy-
pothesize that the efficacy of the EGS-based gene targeting approach
in tissue culture and in animals is regulated by the overall catalytic ef-
ficiency (i.e., Vmax/Km) of the RNase P in hydrolyzing the target
mRNA induced by the EGS. For this hypothesis to be true, an increase
in the efficiency of RNase-P-associated cleavage mediated by EGS
should result in better inhibitory effects on targeted mRNA expres-
sion in cultured cells and living organisms such as mice.
Our study provides direct evidence that an engineered EGS selected
in vitro (i.e., mCSP-V832) is 60-fold more active [Vmax(apparent)/
Km(apparent)] in guiding RNase P to produce a cleavage in the mCSP
mRNA sequence in vitro than the EGS (i.e., mCSP-SER) originating
from the naturally occurring tRNASer sequence. The variant mCSP-
V832 seemed to be better in reducing mCSP/assemblin expression
and viral replication in tissue culture and mice than mCSP-SER.
On the other hand, we documented a decrease of less than 10% in
mCSP/assemblin expression and MCMV replication in cells and
mice expressing control EGSs mCSP-SER-C, mCSP-V832-C, or
TK112. EGSs mCSP-SER-C and CSP-V832-C had binding affinities
to ms38 comparable to mCSP-SER and mCSP-V832, respectively
(Table 1). However, they could not direct RNase P to cleave the sub-
strate, because the nucleotide changes at their T-loop regions pre-
vented RNase P interaction (Figure 1; Table 1). These observations
indicate that the detected suppression of viral gene expression and
replication in cells and mice expressing mCSP-V832 and mCSP-
SER can be credited to RNase-P-mediated cleavage of the target
mCSPmRNA stimulated by the two EGSs as opposed to the antisense
effect or additional nonspecific effects from the EGSs. Likewise, the
experiments indicate that mCSP-V832, which has better activity
[i.e., Vmax(apparent)/Km(apparent)] to stimulate RNase P-associated
cleavage of mCSP mRNA sequence in vitro, is also more effective in
blocking MCMV gene expression and replication in tissue culture
and mice than mCSP-SER. Our findings support the notion that
increasing the efficiency of EGS to induce RNase P to cleave a target
mRNAmay help enhance the effects on inhibition of gene expression
in tissue culture and in animals in vivo.
The results presented in this study imply that the EGS variants are
stably expressed and active in blocking gene expression in vivo and
that blockage of MCMV mCSP expression and infection in mice is
the direct consequence of the activity of the EGSs to direct RNase
P to hydrolyze the mCSP mRNA. First, we could detect noticeable
levels of EGS RNAs in cultured cells and different organs of mice
such as livers and spleens. Second, in ourMTT experiments, we found
no differences in growth and viability between cell lines expressingMolecular Therapy: Nucleic Acids Vol. 9 December 2017 327
Figure 4. Inhibition of MCMV mRNA and Protein Expression in Mice Transfected with EGS Constructs
Expression of EGS (A) and MCMVmRNAs (B) and protein (C) in mice. Experimental details are described in Materials and Methods. RNA (30 mg) and protein (60 mg) samples
were isolated from livers of MCMV-infected mice receiving PBS only () and PBS containing EGS constructs at 14 days postinfection. RNA samples were separated on
2%-formaldehyde-containing agarose gels (lanes 1–8) or 8%-urea-containing polyacrylamide gels (lanes 9–12). Protein samples were separated on 9% SDS polyacrylamide
gels (lanes 13–20). The separated RNA and protein fractions were reacted with a [32P]-radiolabeled probe for the DNA sequences coding for mouse RNase P RNA (lanes
1–4), EGSs (lanes 5–8),3 and mCSP mRNA (9–12) or antibodies against mouse actin (lanes 13–16) and MCMV mCSP (lanes 17–20).
Molecular Therapy: Nucleic Acidsengineered EGSs and parental cells for up to 90 days. After hydrody-
namic transfection of the LXSN-EGS plasmids, uninfected mice
showed no adverse symptoms for 3 months compared to the mice
that received PBS only (data not shown). These observations suggest
that expressing these EGSs may be non-toxic to cells and animals.
Third, EGS RNAs specifically repressed mCSP/assemblin expression.
Expression levels of other MCMV genes such as M36, mie1, M44,
M112, and M99 were not altered in cells that expressed the EGSs
(Table 2). Furthermore, EGSs seemed to be functional in guiding
RNase P to cleave target mCSP mRNA in mice. Decreased mCSP
expression, reduced viral titers, and enhanced survivability were
documented in mice receiving mCSP-V832 andmCSP-SER plasmids,
but not in mice receiving PBS only or PBS with control EGS mCSP-
SER-C, mCSP-V832-C, or M1-TK constructs. These findings suggest
that EGSs effectively direct RNase P to cleave the target mCSPmRNA
in vivo, leading to decreased mCSP expression, reduced MCMV
production, and improved survivability in the infected animals.
HCMV infection can be devastating and fatal to individuals with
immune system deficiencies, such as recipients of organ transplants
and AIDS patients. MCMV infection of SCIDmice represents a desir-
able animal model in which to assess CMV pathogenesis in
hosts16,39–41 and assay the efficacy of new antiviral therapeutics.17,18
Hydrodynamic transfection via tail vein injection has been demon-
strated to transfer plasmid DNA to the livers and spleens with high
speed and efficiency.21–23 Although it is not applicable clinically,
the hydrodynamic transfection technique is valuable to validate feasi-
bility of delivering innovative therapeutics into animals and assess
their functionality and potency in vivo.21–23 As a herpesvirus,42
CMV is known to establish latent infection in bone marrow progen-
itor cells and create devastating consequences by spreading to other
tissues from the bonemarrow.17,18 One potential anti-CMV approach
is to transfer EGS expression cassettes to the progenitor cells associ-328 Molecular Therapy: Nucleic Acids Vol. 9 December 2017ated with the bone marrow, such as CD34+ cells, and express EGSs
to control viral infection in these cells and in vivo.
Compared to other nucleic-acid-based gene-interfering approaches
such as antisense oligonucleotides and RNAi, the EGS-based technol-
ogy is unique, as this method induces RNase P to cleave the target
mRNAs. In an elegant study by Stein and colleagues, RNase-P-medi-
ated cleavage is specific and does not generate non-specific “irrelevant
cleavage” that is associated with RNase-H-mediated cleavage induced
by antisense phosphorothioate oligonucleotides.10 Furthermore,
recent studies, as well as this study, show that EGSs effectively block
gene expression in both cultured cells and animals and that they may
be as effective as small interfering RNAs (siRNAs) and ribozymes in
knocking down gene expression.8–14 Thus, EGSs represent a new and
promising class of nucleic-acid-based gene-interfering reagents for
therapeutic application. Further studies on the effectiveness of the
EGS-based approach and other nucleic-acid-based gene-interfering
approaches should reveal the advantages and shortcomings of the
EGSs compared to other DNA/RNA-based gene targeting molecules.
Because CMV is a DNA virus, genome editing approaches such as the
transcription activator-like effector nuclease (TALEN) and CRISPR/
CAS9 systems may be advantageous by targeting the viral genomic
DNA.43,44 However, the efficacy of these genome editing approaches
in reducing viral genomic DNA levels has not yet been determined,45
while knocking down viral essential mRNA expression by numerous
methods such as RNAi and RNase P has been shown to yield impres-
sive inhibition of viral infection and replication.1–4 Further studies to
evaluate the effectiveness of both genome editing approaches and
mRNA-targeting strategies should facilitate the development of these
methods for gene-targeting applications.
Little is known about the toxicity of the EGS molecules. Our results
presented in this study suggest that expression of EGSs in cultured
Figure 5. Survival of MCMV-Infected CB17 SCID Mice Hydrodynamically
Transfected with PBS Alone or PBS with Different LXSN-EGS DNA
Mice (5 animals per group) were infected intraperitoneally by MCMV and transfected
hydrodynamically. Experiments were performed as described in Materials and
Methods. We assessed animal survival for at least 90 days postinfection.
www.moleculartherapy.orgcells and mice does not significantly affect the viability of the cells and
animals. Further studies on the toxicity of the EGSs are needed in
order to determine whether EGS molecules exhibit significant cyto-
toxicity. Equally elusive is the sequence specificity and off-target
effects of the EGS-based technology. The EGS targeting specificity
is determined by two different interactions between the EGS and
target mRNA.3,4 The first interaction is the base-pairing between
the target mRNA and the antisense domain of the EGS. The second
interaction is between the mRNA and RNase P recognition domain
of the EGS (e.g., T-loop). This second interaction stabilizes the
mRNA-EGS complex to fold into a tRNA-like molecule. It is conceiv-
able that modulating the second interaction would potentially
enhance the sequence specificity of the EGS-based technology and
reduce potential off-target effects. Using northern blot analyses and
RACE PCR assays, we detected no specific products of RNase P cleav-
age of viral mRNAs in these cells, possibly because these cleavage
products, which are RNAs lacking either a 50 cap structure or a
30 poly(A) sequence, are extremely unstable and quickly hydrolyzed
intracellularly. Additional studies on these issues will reveal the action
and sequence specificity of the EGS technology.
In vitro selection allows us to engineer functional RNAmolecules that
have enhanced activity.46–48 Additionally, this technique has been
applied to give rise to EGSs capable of inducing RNase-P-mediated
cleavage of various mRNAs.15,32 However, there was no report using
the selected EGS variants to modulate gene expression in animals. In
this study, EGSs selected in vitro with enhanced targeting activity also
displayed superior efficacy in suppressing MCMV mCSP and assem-
blin expression and viral production in tissue culture and in mice.Hence, our study offers a way for the manufacturing of potent
EGSs by taking advantage of a selection procedure and optimizing
EGS to hybridize with designated mRNAs. Additional research
involving the use of EGS in animals will expedite the development
of better EGS-based therapeutics.
MATERIALS AND METHODS
Ethics Statement
We performed the study strictly according to the recommendations in
the Guide for the Care and Use of Laboratory Animals from the NIH.
The experimental procedures for all animal studies were approved
either by the Animal Care and Use Committee of the University of
California, Berkeley (protocol R240) or by the Animal Care and
Use Committee of the College of Life Sciences and Technology, Jinan
University (Guangzhou, China). All efforts were made to mitigate any
suffering experienced by the animals.
EGS Studies In Vitro
We generated the EGS coding sequences by PCR using pV832 and
pTK11234 as the templates according to previously published
methods.15,34 The 50 PCR primer for mCSP-SER and mCSP-SER-C
was SER-5 (50-GGAATTCTAATACGACTCACTATAGGTTAAC
TCCGTAAGTGCGGTCTCCGCGC-30). The 30 primers for mCSP-
SER and mCSP-SER-C were SER-3 (50-AAGCTTTAAATGCCC
TCTGCAGGATTTGAACCTGCGCGCGGAGACCGCAC-30) and
SER-C-3 (50-AAGCTTTAAATGCCCTCTGCAGGATTTCTTCCT
GCGCGCGGAGACCGCAC-30), respectively. The 50 primer for
CSP-V832 and CSP-V832-C was V832-5 (50-GGAATTCTAATA
CGACTCACTATAGGTTAAC TCCGTAA GTTGAGCGTGA-30).
The 30 primers for mCSP-V832 and mCSP-V832-C were V832-3
(50-AAGCTTTAAATGCCCTCTTAGCAGCTCGAA GCTATCAC
GCTCAA-30) and V832-C-3 (50-AAGCTTTAAATGCCCTCTTAG
CAGCTCCTT GCTATCACGCTCAA-30), respectively. We gener-
ated the DNA sequence coding substrate ms38 by PCR using
pGEM3zf(+) as a template with the 50 primer ms38-5-AF25
(50-GGAATTCTAATACGACTCACTATAG-30) and the 30 primer
ms38-3 (50-CGGGATCCGCATTCCGTAATAAGAGGGCACCTG
AGGCACCTATAGTGAGTCGTATTA-30).
Mouse RNase P was obtained from lysates of NIH 3T3 cells as previ-
ous noted.14,32 The EGS and [32P]-labeled MCMV mCSP mRNA
substrate was mixed with mouse RNase P at 37C in buffer A, which
comprised 50 mMTris (pH 7.4), 100 mMNH4Cl, and 10 mMMgCl2.
We then employed electrophoresis to separate the reaction mixtures
with denaturing gels and used a STORM840 phosphorimager to
analyze the results. Experiments to obtain the values of Vmax and
Km were assayed under multiple turnover settings as noted
earlier.14,15,32
The equilibrium dissociation constants (KD) of EGSs and substrate
complexes were determined using an electrophoretic mobility shift
assay as described previously.49 Binding assays were performed in
buffer B (50 mM Tris [pH 7.5], 100 mM NH4Cl, 10 mM MgCl2,
3% glycerol, 0.1% xylene cyanol, and 0.1% bromophenol blue).Molecular Therapy: Nucleic Acids Vol. 9 December 2017 329
Figure 6. Inhibition of MCMV Growth in Mice Transfected with EGS Constructs
Titers of MCMV in spleen (A), liver (B), and salivary glands (C) of MCMV-infected CB17 SCID mice hydrodynamically transfected with PBS alone or PBS with different LXSN-
EGS DNA. Experimental details regarding the infection and hydrodynamic transfection of animals are described in Materials and Methods. Different tissues were harvested
from animals at 1, 3, 7, 10, 14, and 21 days postinfection. Viral titers in the tissues were determined by plaque assays. The limit of detection was 10 PFU/mL of the tissue
homogenate. Values were derived from experiments that were in triplicate andrepeated three times.
Molecular Therapy: Nucleic AcidsWe determined the value of KD from a plot of the percentage of
product bound versus EGS concentration.14,15,32 The binding and
cleavage reactions were assayed in triplicate and repeated three
times.
Cells Expressing EGSs
NIH 3T3 cells were transfected with retroviral vector LXSN-EGS
DNAs and then incubated with neomycin (500 mg/mL) to produce
cloned EGS-expressing cell lines, and the expression of EGS and
mouse RNase P RNAs was assayed using northern blot experiments
following previously described protocols.14,15,32
We performed MTT assays (Sigma) to study cytotoxicity of the EGS
expression. At different periods of time, we added MTT (Sigma)
(5 mg/mL in PBS) to cells grown in 96-well plates and examined
cell viability. We assayed the absorbance at 570 nm on a microplate
reader. We carried out experiments in four wells and repeated them
three times. With a Nikon TE300 microscope, we also studied the
morphology of the cells during the experiments.
Levels of Viral mRNA and Protein
In northern blot experiments, total RNA fractions were collected
from cells and tissues, separated in 1% agarose gels containing
formaldehyde, moved to a nitrocellulose film, and hybridized with
[32P]-labeled DNA probes containing the MCMV DNA sequence
or the DNA sequence coding for mouse RNase P RNA.14,15,32 The
images were captured for analysis using a STORM840
Phosphorimager.
In western blot experiments, the polypeptide samples were collected
from cells and tissues, separated on SDS/9% polyacrylamide gels
cross-linked with N,N0 0methylenebisacylamide, moved to a nitrocel-
lulose film, and detected with the antibodies against MCMV proteins
and mouse actin in the presence of a chemiluminescent agent using a
STORM840 phosphorimager.14,15,32 We performed assays in tripli-
cate, and each assay was repeated three times.330 Molecular Therapy: Nucleic Acids Vol. 9 December 2017Levels of Viral DNA
Cells (5 105) cultured in 6-well plates weremock-infected or infected
withMCMV following previously described procedures.19 At 48–96 hr
postinfection, total and encapsidated (DNase-I-treated) DNA was
prepared as described previously and used as templates for PCR.50
The levels of MCMV DNA were measured using a semiquantitative
PCR assay with the amplification of the viral mie1 sequence and using
the mouse b-actin sequence as the internal control.50–52 The primers
and reaction mixture protocols have been described previously.50–52
The PCR reaction had 20 cycles with a denaturing step at 94C for
1 min, followed by an annealing step at 47C for 1 min and an ampli-
fication/extension step at 72C for 10 min. The PCR experimental
conditions were adjusted to guarantee that the amplification was
within the linear range. PCR products were amplified with a-[32P]-
dCTP, subjected to separation on polyacrylamide gels, and detected
using a STORM840 phosphorimager.50 A standard curve was gener-
ated by assaying different concentrations of a template DNA. The
plot for MCMV and actin DNA versus dilutions of DNA did not reach
a plateau, and the ratios of MCMV DNA to actin DNA were similar
among the DNA dilutions, suggesting that the semiquantitative PCR
assay is reproducible and accurate.50–52 PCR results were from exper-
iments that were performed in triplicate and repeated three times.
Studies in Animals
MCMV (Smith strain) (1 104 PFU/animal) was used to infect sets of
4- to 6-week-old CB17 SCIDmice (at least five animals per set) (Jack-
son Laboratory, Bay Harbor, ME) intraperitoneally. At 2 days postin-
fection, we hydrodynamically transfected different constructs to these
mice using previously described protocols.21–23 We used 24G–27G
needles to inject 1–2 mL PBS (based on the ratio of injection volume
to body weight) in the absence or presence of 20 mg LXSN-EGS DNA
within 5–10 s.21–23 We performed hydrodynamic transfection every
3 days after the first injection. Transfection efficiency was determined
by assessing the expression of EGS RNAs within the organs
(e.g., livers) with northern blot experiments and using fluorescent mi-
croscopy to survey GFP expression in cells transfected with EGSs.
www.moleculartherapy.orgFor studies of viral virulence, we observed mice 2 times a day and
documented mortality of infected mice for more than 3 months to
determine survival rates.19 To analyze MCMV growth in the animals,
sets of mice (at least five mice per set) were euthanized at 1, 3, 7, 10,
14, and 21 days postinfection. We collected the organs (i.e., spleens,
livers, and salivary glands) and subjected the samples to sonication
to create suspension samples that contained DMEM and 10% non-
fat milk.We determined the titers of viral samples using plaque assays
following procedures published elsewhere.19 To assay viral gene
expression, total RNA and protein samples were prepared from ho-
mogenized tissue samples and analyzed by northern and western
blot experiments.14,19,32
Analysis of MCMV Growth with Plaque Assays
We collected tissues and cells, transferred them to 10% skimmilk, and
subsequently used sonication to generate virus stocks. Virus stocks
were assayed with plaque assays in NIH 3T3 as explained earlier.19 Ti-
ters were derived from experiments that were in triplicate and
repeated three times. We documented MCMV titers as PFU/mL ho-
mogenized tissues. The detection limit of homogenized tissue was 10
PFU/mL. We assigned a titer of 10 (101) PFU/mL for the samples that
were negative at a 101 dilution.19
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